货号（Catalog No.）

CSD00272

通用名INN

Caplacizumab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Sourceicon

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.

别名(Alternative names)

ALX-0081,PMP12A2h1-linker AAA-PMP12A2h1,caplacizumab-yhdp

靶点;物种(Specificity target name;species)

VWF A1 domain[Homo sapiens]

种类(Species)

Humanized

受体鉴定(Receptor identification)

VH-VH

化学信息n

分子量(MV)

27880.0 Da

CAS:915810-67-2

存储条件(Storage)

store at -80°C

Note
For research use only. Not suitable for clinical or therapeutic use.